Track our publications at Google Scholar or ​Pubmed

Journal Publications
  • Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, Turk P, Bera K, Abraham J, Sikov WM, Somlo G, Harris LN, Gilmore H, Plecha D, Varadan V#, Madabhushi A#. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer. JAMA Network Open. 2019 Apr 5;2(4):e192561. [PMID: 31002322] (# corresponding author)
  • Blum AE, Venkitachalam S, Ravillah D, Chelluboyina AK, Kieber-Emmons AM, Ravi L, Kresak A, Chandar AK, Markowitz SD, Canto MI, Wang JS, Shaheen NJ, Guo Y, Shyr Y, Willis JE, Chak A, Varadan V*, Guda K*, “Systems Biology Analyses Reveal Hyperactivation of Transforming Growth Factor beta and JNK Signaling pathways in Esophageal Cancer,” Gastroenterology, 156(6):1761-1774, 2019. [PMID: 30768984] (* co-senior author)
  • Harbhajanka A, Chahar S, Miskimen K, Silverman P, Harris L, Williams N, Varadan V, Gilmore H "Clinicopathological, ummunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in Triple-Negative Breast Carcinoma," Human Pathology, Jun 9. pii: S0046-8177(18)30213-2, 2018. [PMID: 29894722]
  • Beig N, Patel J, Prasanna P, Hill V, Gupta A, Correa R, Bera K, Singh S, Partovi S, Varadan V, Ahluwalia M, Madabhushi A, Tiwari P "Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma", Scientific Reports, 8(1):7, 2018. [PMID: 29311558]
  • Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML, Ford JM, Stark GR, Jackson MW "Interferon-beta represses cancer stem cell properties in triple-negative breast cancer", Proc. Natl. Acad. Sciences, 114(52):13792-13797, 2017. [PMID: 29229854]
  • Sahni JM, Gayle SS, Webb B, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri P, Varadan V, Summers MK, Keri RA "Mitotic vulnerability in triple-negative breast cancer associated with LIN9 is targetable with BET inhibitors", Cancer Research, 77(19):5395-5408, 2017. [PMID: 28807940]
  • Dimitrova N, Nagaraj AB, Razi A, Singh S, Kamalakaran S, Banerjee N, Joseph P, Mankovich A, Mittal P, DiFeo A#, Varadan V# “InFlo: A Novel Systems Biology Framework Identifies cAMP-CREB1 Axis as a Key Modulator of Platinum Resistance in Ovarian Cancer”, Oncogene, 36(17):2472-2482, 2017. [PMID: 27819677] (#Corresponding author)
  • Kaz AM, Wong CJ, Varadan V, Willis JE, Chak A, Grady WM, “Global DNA methylation patterns in Barrett’s esophagus, dysplastic Barrett’s, and esophageal adenocarcinoma are associated with BMI, gender and tobacco use”, Clinical Epigenetics, 8:111, 2016. [PMID: 27795744]
  • Blum A, Venkitachalam S, Guo Y, Kieber-Emmons AM, Ravi L, Chandar AK, Iyer PG, Canto MI, Wang JS, Shaheen NJ, Barnholtz-Sloan JS, Markowitz SD, Willis JE, Shyr Y, Chak A, Varadan V & Guda K, "RNA Sequencing Identifies Transcriptionally-Viable Gene Fusions in Esophageal Adenocarcinomas," Cancer Research, 76(19):5628-5633, 2016. [PMID: 27503924]
  • Razi A, Afghah F, Singh S, Varadan V#, “Network-based enriched gene subnetwork identification: a game-theoretic approach,” Biomed Eng Comput Biol., 7:1-4, 2016. [PMID: 27081328] (# corresponding author)
  • Venkitachalam S, Revoredo L, Varadan V, Fecteau RE, Ravi L, Lutterbaugh J, Markowitz SD, Willis JE, Gerken TA, Guda K, “Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer,” Scientific Reports, 6:23642, 2016. [PMID: 27004849]
  • Varadan V, Sandoval M, Harris LN, "Biomarkers for Predicting Response to Anti-HER2 Agents," Adv. Exp. Med. Biol., 882:155-167, 2016. [PMID: 26987534]
  • Varadan V#, Gilmore H, Miskimen KLS, Tuck D, Parsai S, Awadallal A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf M, Sikov W, Harris LN#, “Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer,” Clinical Cancer Research, 22:3249-3259, 2016. [PMID: 26842237] (# corresponding author)
  • Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong K, Liu S, Sicinski P, Winer EP, Krop IE & Zhao JJ. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 29(3):255-69, 2016. [PMID: 26977878].
  • Varadan V#, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KLS, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN#, “Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers,” Int. Journal of Cancer, 2015. [PMID: 26284485] (# corresponding author)
  • Varadan V#, Singh S, Nosrati A, Ravi L, Lutterbaugh J, Barnholtz-Sloan JS, Markowitz SD, Willis JE, Guda K#, “ENVE: a novel computational framework characterizes copy-number mutational landscapes in African American colon cancers,” Genome Medicine, 7(1): 69, 2015. [PMID: 26269717] (# corresponding author)
  • Guda K, Veigl ML*, Varadan V*, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JKV, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE, “Novel recurrently mutated genes in African American colon cancers,” Proc. Natl. Acad. Sciences, 112(4):1149-54, 2015.  [PMID: 25583493] (*equal contribution)
  • Wrzeszczynski KO, Varadan V, Kamalakaran S, Levine DA, Dimitrova N, Lucito R, “Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer,” Methods Mol. Biol., 1049:35-51, 2013. [PMID: 23769412]
  • Kamalakaran S, Varadan V, Janevski A, Banerjee N, Tuck D, McCombie R, Dimitrova N, Harris LN, “Translating Next Generation Sequencing to practice: opportunities and necessary steps,” Molecular Oncology, 2013. [PMID: 23769412]
  • Wang S, Wang L, Bayaxi N, Li J, Verhaegh W, Janevski A, Varadan V, et al, “A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue”, Gut, 62(2):280-9, 2013. [PMID: 22535378]
  • Tang MH, Varadan V, Kamalakaran S, Zhang MQ, Dimitrova N, Hicks J, “Major chromosomal breakpoint intervals in breast cancer co-localize with differentially methylated regions”, Frontiers in Oncology, 2:197, 2012. [PMID: 23293768]
  • Janevski A, Varadan V, Kamalakaran S, et.al, “Effective normalization for copy number variation detection from whole genome sequencing”, BMC Genomics, 13 Suppl 6:S16, 2012. [PMID: 23134596]
  • Varadan V, Mittal P, Vaske CJ, Benz SC, “The integration of biological pathway knowledge in cancer genomics: a review of existing computational approaches”, IEEE Signal Processing Magazine, 29(1):35-50, 2012.
  • Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, et al, “Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer”, PLoS One, 6(12):e28503, 2011. [PMID: 22174824]
  • Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables, Molecular Oncology, 2011. [PMID: 21169070]
  • Kim H, Watkinson J, Varadan V, Anastassiou D, “Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1”, BMC Medical Genomics, 3:51, 2010. [PMID: 21047417]
 
Full-length Peer-reviewed Conference Publications
  • Razi A, Banerjee N, Dimitrova N, Varadan V, "Non-Linear Bayesian Framework to Detect Functional Aberrations Driving Inconsistencies in Gene Regulatory Networks", IEEE Engg. in Medicine & Biology (EMBC), Italy, 2015.
  • Razi A, Afghah F, Varadan V, "Identifying Gene Subnetworks Associated with Clinical Outcome in Ovarian Cancer Using Network Based Coalition Game", IEEE Engg. in Medicine & Biology (EMBC), Italy, 2015.
  • Varadan V, Agrawal V, Harris L, Dimitrova N, "Identification and characterization of gene fusions in breast cancer - A non-trivial pursuit," IEEE Global Conf. on Signal and Information Processing (GlobalSIP), 3-5 Dec. 2013.
  • Varadan V, Janevski A, Kamalakaran S, Banerjee, N, Dimitrova, N, Harris LN, "Statistical assessment of gene fusion detection algorithms using RNA Sequencing Data," IEEE Stat. Sig. Proc. Workshop (SSP), 5-8 Aug. 2012.
  • Janevski A, Varadan V, Kamalakaran S, Banerjee N, Dimitrova N, "Comparative copy number variation from whole genome sequencing," 2011 IEEE Intl. Workshop on Genomic Sig. Proc. and Stat. (GENSIPS), 4-6 Dec. 2011.
  • Tang ME, Varadan V, Kamalakaran S, Zhang MQ, Dimitrova, N, Hicks J, "A method for finding novel associations between genome-wide copy number and DNA methylation patterns," 2011 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS), 4-6 Dec. 2011.
  • Banerjee N, Janevski A, Kamalakaran S, Varadan V, Lucito R, Dimitrova N, "Pathway and network analysis probing epigenetic influences on chemosensitivity in ovarian cancer," 2010 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS),10-12 Nov. 2010.
 
Invited Talks and Podium Presentations
  • Varadan V, Miskimen K, Parsai S, Krop IE, Winer EP, Bossuyt V, Abu-Khalaf M, Sikov W, Harris L., “A discovery and validation set of breast cancer preoperative trials show an increase in Immune Score upon brief-exposure to trastuzumab and the HER2-enriched subtype predict response to combination chemotherapy and trastuzumab,” AACR Annual Meeting 2015 Minisymposium on Clinical Research, Philadelphia, PA, April 2015 (Oral presentation).
  • Varadan V, “Clinical Grade Gene Expression Signature Development using RNA-seq”, 2nd Annual The Clinical Genome Conference, San Francisco, June 2013 (Invited Talk).
  • Varadan V, Miskimen K, Kamalakaran S, Janevski A, Banerjee N, Williams N, Abu-Khalaf M, Sikov W, Dimitrova N, Harris L, “RNA-seq identifies a TGF-β signature that predicts response to preoperative bevacizumab in breast cancer”, AACR Annual Meeting 2013 Minisymposium on Novel Biomarkers of Drug Response, Washington DC, April 2013 (Oral presentation).